このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

BioAtla 将来の成長

Future 基準チェック /06

BioAtlaは、3.7%と73.5%でそれぞれ年率3.7%で利益と収益が成長すると予測される一方、EPSはgrowで21.6%年率。

主要情報

3.7%

収益成長率

21.6%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	73.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGM:BCAB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	7	-138	-134	N/A	3
12/31/2025	N/A	-113	-110	-93	4
12/31/2024	N/A	-89	-87	-98	5
3/31/2024	N/A	-119	-112	-112	N/A
12/31/2023	N/A	-123	-104	-104	N/A
9/30/2023	N/A	-124	-99	-98	N/A
6/30/2023	N/A	-117	-95	-95	N/A
3/31/2023	N/A	-110	-88	-88	N/A
12/31/2022	N/A	-106	-91	-90	N/A
9/30/2022	N/A	-102	-87	-87	N/A
6/30/2022	N/A	-99	-76	-76	N/A
3/31/2022	0	-101	-73	-72	N/A
12/31/2021	0	-95	-63	-62	N/A
9/30/2021	0	-79	-57	-55	N/A
6/30/2021	0	-68	-59	-58	N/A
3/31/2021	0	-44	-49	-48	N/A
12/31/2020	0	-27	-37	-36	N/A
9/30/2020	3	-22	-25	-24	N/A
12/31/2019	5	-29	-11	-10	N/A
12/31/2018	11	-28	-36	-35	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BCAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BCAB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BCAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BCAB来年は収益がないと予測されています。

高い収益成長: BCAB来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BCABの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

BioAtla 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 9.4% to US$15.25

Consensus EPS estimates fall by 13%

Price target decreased by 8.2% to US$24.00

Price target decreased by 8.5% to US$24.71

Price target decreased to US$27.00

Price target decreased to US$41.17

Recent updates

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Financial position

BioAtla, Inc. to Report Q1, 2024 Results on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla, Inc., Annual General Meeting, Jun 13, 2024

BioAtla, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Shareholder dilution

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Co-Founder recently bought US$107k worth of stock

Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types

BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

BioAtla, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Price target decreased by 9.4% to US$15.25

Consensus EPS estimates fall by 13%

BioAtla, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

BioAtla, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently bought US$101k worth of stock

Price target decreased by 8.2% to US$24.00

Price target decreased by 8.5% to US$24.71

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

High number of new and inexperienced directors

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Price target decreased to US$27.00

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Co-Founder recently bought US$207k worth of stock

BioAtla reports Q2 results

BioAtla, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 2000 Growth Index

VP of Finance recently bought US$151k worth of stock

Bioatla, Inc. Announces Executive Changes, Effective June 16, 2022

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Price target decreased to US$41.17

High number of new directors

BioAtla, Inc., Annual General Meeting, Jun 16, 2022

BioAtla, Inc. to Report Q1, 2022 Results on May 04, 2022

Consensus forecasts updated

Price target decreased to US$44.40

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$59.60

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Chief Financial Officer recently sold US$333k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$1.2m worth of stock

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in 3Q 2020)

Independent Director notifies of intention to sell stock

President & Director recently sold US$90k worth of stock

President & Director recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall to US$17.6m

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 3000E Value Index

Co-Founder recently sold US$5.0m worth of stock

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

BioAtla Conditionally Active Biologic Antibody Design And Functionality For Cancer Treatment Described In Leading Scientific Journal Peer-Reviewed Paper

BioAtla, Inc. has completed an IPO in the amount of $189 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘